TY - JOUR
T1 - Is there an optimal irradiation dose for photodynamic therapy
T2 - 37 Jcm-2 or 75 Jcm-2?
AU - Todd, B.
AU - Lesar, A.
AU - O'Mahoney, P.
AU - Eadie, Ewan
AU - Ibbotson, Sally
N1 - © 2019 British Association of Dermatologists.
PY - 2020/5
Y1 - 2020/5
N2 - Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen’s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).
AB - Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen’s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).
UR - http://www.scopus.com/inward/record.url?scp=85076725611&partnerID=8YFLogxK
U2 - 10.1111/bjd.18644
DO - 10.1111/bjd.18644
M3 - Letter
C2 - 31677268
SN - 0007-0963
VL - 182
SP - 1287
EP - 1288
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 5
ER -